[미국특허]
Method for assessing metastatic properties of breast cancer
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
G01N-033/53
C12Q-001/68
출원번호
US-0536440
(2003-11-27)
등록번호
US-8163494
(2012-04-24)
국제출원번호
PCT/IL03/01008
(2003-11-27)
§371/§102 date
20051114
(20051114)
국제공개번호
WO2004/047720
(2004-06-10)
발명자
/ 주소
Neufeld, Gera
Akiri, Gal
Vadasz, Zahava
Gengrinovitch, Stela
출원인 / 주소
Technion Research & Development Foundation Ltd.
대리인 / 주소
Morrison & Foerster LLP
인용정보
피인용 횟수 :
14인용 특허 :
55
초록
Methods and compositions suitable for modulating angiogenesis in a mammalian tissue are provided. Further provided are methods suitable for inhibiting metastasis and fibrosis in a mammalian tissue and for assessing the malignancy of colon cancer tumors.
대표청구항▼
1. A method of determining that a breast tumor is metastatic, the method comprising: (a) obtaining a first sample of breast tumor tissue from a subject;(b) obtaining a second sample of breast tumor tissue, which is non-metastatic; and(c) determining that a tissue level and/or an activity level of a
1. A method of determining that a breast tumor is metastatic, the method comprising: (a) obtaining a first sample of breast tumor tissue from a subject;(b) obtaining a second sample of breast tumor tissue, which is non-metastatic; and(c) determining that a tissue level and/or an activity level of a polypeptide set forth in SEQ ID NO: 2 is higher in the first breast tumor tissue sample than in the second breast tumor tissue sample;thereby determining that the tumor from which the first sample was derived is metastatic. 2. The method of claim 1, wherein said determining in step (c) is effected by an immunological detection method and/or an RNA detection method. 3. The method of claim 1, wherein said determining in step (c) is effected by an enzymatic activity detection method. 4. The method of claim 2, wherein said determining in step (c) is effected by the immunological detection method, which is selected from the group consisting of a radio-immunoassay (RIA), an enzyme linked immunosorbent assay (ELISA), a Western blot analysis, and an immunohistochemical analysis. 5. The method of claim 2, wherein said determining in step (c) is effected by the RNA detection method, which is selected from the group consisting of a Northern blot analysis, an RNA in situ hybridization stain, an RT-PCR analysis, and an in situ RT-PCR stain. 6. The method of claim 3, wherein said enzymatic activity detection method is selected from the group consisting of a cytochemical stain, an in vitro activity assay, and an activity gel. 7. The method of claim 2, wherein the samples in step (c) are contacted with an antibody to LOR-1, such that LOR-1 in one or both of the samples forms a complex with the antibody, and the antibody-LOR-1 complex is detected. 8. The method of claim 2, wherein the samples in step (c) are contacted with a nucleic acid probe homologous to the LOR-1 gene, such that LOR-1 mRNA in one or both of the samples forms hybrids with the probe, and the hybrids are detected. 9. The method of claim 2, wherein the samples in step (c) are contacted with an antibody raised against LOR-1. 10. The method of claim 7, wherein the samples in step (c) are contacted with an antibody raised against LOR-1. 11. The method of claim 9, wherein the LOR-1 is human LOR-1. 12. The method of claim 10, wherein the LOR-1 is human LOR-1. 13. A method of determining that a breast tumor is metastatic or invasive, the method comprising: (a) obtaining a sample of breast tumor tissue from a subject; and(b) determining a tissue level and/or an activity level of a polypeptide set forth in SEQ ID NO: 2 in the breast tumor tissue sample;wherein a higher tissue level and/or activity level of said polypeptide, compared with that of a non-metastatic breast tumor tissue sample, indicates that the tumor from the subject is metastatic or invasive. 14. The method of claim 13, wherein said determining in step (b) is effected by an immunological detection method and/or an RNA detection method. 15. The method of claim 13, wherein said determining in step (b) is effected by an enzymatic activity detection method. 16. The method of claim 14, wherein said determining in step (b) is effected by the immunological detection method, which is selected from the group consisting of a radio-immunoassay (RIA), an enzyme linked immunosorbent assay (ELISA), a Western blot analysis, and an immunohistochemical analysis. 17. The method of claim 14, wherein said determining in step (b) is effected by the RNA detection method, which is selected from the group consisting of a Northern blot analysis, an RNA in situ hybridization stain, an RT-PCR analysis, and an in situ RT-PCR stain. 18. The method of claim 15, wherein said enzymatic activity detection method is selected from the group consisting of a cytochemical stain, an in vitro activity assay, and an activity gel. 19. The method of claim 14, wherein the sample in step (b) is contacted with an antibody to LOR-1, such that LOR-1 in the sample forms a complex with the antibody, and the antibody-LOR-1 complex is detected. 20. The method of claim 14, wherein the sample in step (b) is contacted with a nucleic acid probe homologous to the LOR-1 gene, such that LOR-1 mRNA in the sample forms hybrids with the probe, and the hybrids are detected. 21. The method of claim 14, wherein the sample in step (b) is contacted with an antibody raised against LOR-1. 22. The method of claim 19, wherein the sample in step (b) is contacted with an antibody raised against LOR-1. 23. The method of claim 21, wherein the LOR-1 is human LOR-1. 24. The method of claim 22, wherein the LOR-1 is human LOR-1. 25. A method of determining that a breast tumor is metastatic, the method comprising: (a) assaying a tissue sample of the breast tumor for a tissue level and/or an activity level of a polypeptide set forth in SEQ ID NO: 2; and(b) determining that the tissue level and/or the activity level is higher in the breast tumor tissue sample than in a non-metastatic breast tumor tissue sample,thereby determining that the assayed tumor is metastatic. 26. The method of claim 25, wherein the determining in step (b) is effected by an immunological detection method and/or an RNA detection method. 27. The method of claim 25, wherein the determining in step (b) is effected by an enzymatic activity detection method. 28. The method of claim 26, wherein the sample is contacted with an antibody to LOR-1, such that LOR-1 in the sample forms a complex with the antibody, and the antibody-LOR 1 complex is detected. 29. The method of claim 26, wherein the sample is contacted with a nucleic acid probe homologous to the LOR-1 gene, such that LOR-1 mRNA in the sample forms hybrids with the probe, and the hybrids are detected. 30. The method of claim 26, wherein the sample is contacted with an antibody raised against LOR-1. 31. The method of claim 28, wherein the sample is contacted with an antibody raised against LOR-1. 32. The method of claim 30, wherein the LOR-1 is human LOR-1.
Kagan Herbert M. (Arlington MA) Gacheru Stephen N. (Worcester MA), Anti-fibrotic agents and methods for inhibiting the activity of lysyl oxidase in-situ using adjacently positioned diamin.
Garcia Fernando S. (Eden Prairie MN) Ginnow-Merkert Hartmut (Eden Prairie MN) Anderson Paul J. (Eden Prairie MN) Hudson Bertram J. (Eden Prairie MN), Glucose medical monitoring system.
Wands Jack R. (Waban MA) Zurawski ; Jr. Vincent R. (West Chester PA) Schoemaker ; Hubert J. P. (Newton MA), Immunoassay utilizing monoclonal high affinity IgM antibodies.
McCarthy James R. (West Chester OH) Barney Charlotte L. (Cincinnati OH) Matthews Donald P. (West Chester OH) Bey Philippe (Cincinnati OH), Inhibitors of lysyl oxidase.
Evans,Mark J.; Scicchitano,Marshall S.; Bapat,Ashok R.; Bhat,Ramesh A.; Mastroeni,Robert; Karathanasis,Sotirios K., Member of the lysyl oxidase gene family.
Evans,Mark J.; Scicchitano,Marshall S.; Bapat,Ashok R.; Bhat,Ramesh A.; Mastroeni,Robert; Karathanasis,Sotirios K., Member of the lysyl oxidase gene family.
Smulson Mark E. (Washington DC) Bhatia Kishor (Arbutus MD) Huppi Konrad (Reston VA), Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for hu.
Kim, Byung chul; Kim, Jhin gook; Hur, Nam; Lee, Kyu sang; Son, Dae soon; Park, Kyung hee; Ahn, Tae jin, Method of predicting risk of lung cancer recurrence, and a composition, kit and microarray for the same.
Hung Mien-Chie (Houston TX) Yu Di-Hua (Houston TX) Matin Angabin (Houston TX), Methods for the suppression of neu mediated tumors by adenoviral E1A and SV40 large T antigen.
Simonsson Leif R. (Hisings Backa SEX) Arielly Salo (Kungsbacka SEX) Aurell Leif E. (SrSEX) Claeson Karl G. (Linding SEX), Peptide substrates for determination of protease activity.
Surani Azim M. (Cambridge GB3) Neuberger Michael S. (Cambridge GB3) Bruggemann Marianne (Cambridge GB3), Production of antibodies from transgenic animals.
Cabilly Shmuel (Monrovia CA) Heyneker Herbert L. (Burlingame CA) Holmes William E. (Pacifica CA) Riggs Arthur D. (La Verne CA) Wetzel Ronald B. (San Francisco CA), Recombinant immunoglobin preparations.
Cox, III, George Norbert; Case, Casey Christopher; Eisenberg, Stephen P.; Jarvis, Eric Edward; Spratt, Sharon Kaye, Regulation of endogenous gene expression in cells using zinc finger proteins.
Griss ; deceased Gerhart (late of Biberach DEX by Elisabeth Griss ; legal representative) Hurnaus Rudolf (Biberach DEX) Kobinger Walter (Vienna ATX) Pichler Ludwig (Vienna ATX) Bauer Rudolf (Wiesbade, Tetrahydro-benzthiazoles, the preparation thereof and their use as intermediate products or as pharmaceuticals.
Griss ; deceased Gerhart (late of Biberach DEX by Elisabeth Griss ; legal representative) Schneider Claus (Ingelheim am Rhein DEX) Hurnaus Rudolf (Biberach DEX) Kobinger Walter (Vienna ATX) Pichler L, Tetrahydro-benzthiazoles, the preparation thereof and their use as intermediate products or as pharmaceuticals.
Griss ; deceased Gerhart (late of Biberach DEX by Elisabeth Griss ; legal representative) Schneider Claus (Ingelheim am Rhein DEX) Hurnaus Rudolf (Biberach DEX) Kobinger Walter (Vienna ATX) Pichler L, Tetrahydro-benzthiazoles, the preparation thereof and their use as intermediate products or as pharmaceuticals.
Lonberg Nils (San Francisco CA) Kay Robert M. (San Francisco CA), Transgenic non-human animals capable of producing heterologous antibodies of various isotypes.
Smith, Victoria; Ogg, Scott; Van Vlasselaer, Peter; Barry, Vivian E.; Marshall, Derek; Holzer, Alison Kay; Rodriguez, Hector; Oyasu, Miho; McCauley, Scott Alan; Garcia, Carlos Aurelio; Biermann, Donna Hiroko Tokuoka, Methods and compositions for treatment and diagnosis of fibrosis, tumor invasion, angiogenesis, and metastasis.
Smith, Victoria; Ogg, Scott; Van Vlasselaer, Peter; Barry, Vivian E.; Marshall, Derek; Holzer, Alison Kay; Rodriguez, Hector; Oyasu, Miho; McCauley, Scott Alan; Garcia, Carlos Aurelio; Biermann, Donna Hiroko Tokuoka, Methods and compositions for treatment and diagnosis of fibrosis, tumor invasion, angiogenesis, and metastasis.
Neufeld, Gera; Akiri, Gal; Vadasz, Zahava; Gengrinovitch, Stela, Pharmaceutical compositions and methods useful for modulating angiogenesis, inhibiting metastasis and tumor fibrosis, and assessing the malignancy of colon cancer tumors.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.